Swiss drug company Actelion expects an average annual per-patient price for its new pulmonary arterial hypertension medicine in the United States of $160,000 to $170,000, before rebates, chief operating officer Otto Schwarz told analysts on Tuesday.
The drug, Uptravi, won approval from the US FDA last month and went on sale this week, giving doctors another option to treat the deadly disease that kills victims within a few years.
Actelion declined to give forecasts for Uptravi’s average price after rebates or say how many patients could be eligible annually for the treatment to open pulmonary arteries, easing pressure on the heart.
- Disorders & Diseases
- Public Health
- Products & Treatment
- Department Management
- Edition Archive